Mature tertiary lymphoid structure associated CD103+ CD8+ Trm cells determined improved anti-tumor immune in breast cancer

成熟的三级淋巴结构相关 CD103+ CD8+ Trm 细胞确定可改善乳腺癌的抗肿瘤免疫

阅读:34
作者:Qin Fang #, Shuru Chen #, Xiaoyue Chen, Wei Zou, Di Chen, Yukang Huang, Chucheng Wu

Background

Although tertiary lymphoid structures (TLS) play crucial roles in the anti-tumor immune response and are associated with favorable prognoses in many solid tumors, the precise mechanisms by which TLSs enhance anti-tumor immunity remain poorly understood. The current study aimed to explore the relationship between the maturity of tertiary lymphoid structures and their key immune cells in combating breast cancer. Patients and

Conclusion

Our study identifies potential additional prognostic information for the clinical prognosis of breast cancer patients, underscoring the prognostic significance of immune cells within TLS, with a particular focus on CD103+ CD8+ Trm cells and NK cells.

Methods

In this study, we utilized immunofluorescence and H&E staining to detect tumor-resident memory T cells (Trm) and assess the maturity of TLS, analyzing their distribution and proportion in an annotated cohort of 95 breast cancer patients.

Results

The presence of tumor-associated TLSs was correlated with an improved prognosis in patients with breast cancer. The proportion of CD8+CD103+ resident memory T cells and natural killer (NK) cells within the TLSs was significantly higher than that in areas outside of these structures. Additionally, the proportions of CD103+ CD8+ Trm cells and NK cells were significantly increased with the gradual maturation of TLS. Furthermore, the secretion function of effector molecules by CD8+ CD103+ Trm cells and NK cells within TLSs was significantly enhanced, indicating a strong correlation between the effector function of CD103+ CD8+ Trm and NK cells and the maturity of TLSs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。